CPMDOTCPharmaceutical PreparationsFiscal year ends December 31

CANNAPHARMARX, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026

$0.00+0.00 (0.00%)

Close on Oct 16, 2026

Market cap: $1.36M
P/E (TTM): –
Dividend yield: –

CANNAPHARMARX, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	1.36	0.82	0	0	0	0	0	0	0	0	0	0	0	–	–	–	–
Cost of Revenue	3.45	3.76	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gross Profit	-2.08	-2.93	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Research & Development	–	–	–	–	–	–	–	–	–	–	–	0.32	–	–	–	–	–
Selling, General & Admin	–	0.12	0.70	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	0.49	0.15	0.70	2.23	0.85	2.15	0.48	0.01	0.01	0.28	4.22	0.43	0.08	0.09	0.10	0.09	0.09
Advertising Expenses	–	–	–	–	–	–	–	–	–	–	0.03	0.14	0	–	–	–	–
Operating Expenses	1.26	0.70	1.58	5.21	2.99	14	16	0.95	0.01	1.00	12	3.97	0.08	0.09	0.10	-0.59	-0.11
Operating Income	-3.35	-3.63	-1.58	-5.21	-2.99	-14	-16	-0.95	-0.01	-1.00	-12	-3.97	-0.08	-0.09	-0.10	0.59	0.11
Interest Expense	1.96	2.26	1.69	2.29	1.51	2.29	4.47	2.14	0	0.00	0.00	0.01	–	–	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	0	0.00	–	–	–	–	–
Other Non-Operating Income	-7.78	-6.27	5.27	-3.32	-5.84	-5.40	-4.47	-2.14	0	0.00	-0.09	0.00	-0.01	-0.01	0.00	-0.01	0.00
Asset Impairment Charges	–	–	–	–	0.15	7.96	0	–	0	0	0	0	–	–	–	–	–
Gain (Loss) on Investments	–	0	-0.08	0	-6.67	0	-7.07	0	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	0	-0.09	0	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	0	0.14	0	–	–	–	–	–
Pretax Income	–	–	–	-8.53	-8.83	-20	-20	-3.09	-0.01	-1.00	-12	-3.98	-0.09	-0.10	-0.10	0.58	0.11
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	–	–	–	–
Net Income incl. Noncontrolling Interests	-11	-9.91	3.69	–	-8.83	-20	–	–	–	–	–	–	–	–	–	–	–
Net Income	-11	-9.91	3.69	-8.53	-8.83	-20	-20	-3.09	-0.01	-1.00	-12	-3.98	-0.09	-0.10	-0.10	-0.10	0.11
EPS (Basic)(per share)	–	–	0.01	-0.04	0.12	-0.49	-0.66	-0.17	0.00	-0.06	-0.77	-0.36	-0.04	-0.04	-0.04	0.24	–
EPS (Diluted)(per share)	-0.02	-0.02	0.01	-0.04	0.12	-0.49	-0.66	-0.17	0.00	-0.06	-0.77	-0.36	-0.04	-0.04	-0.04	0.24	–
Shares Outstanding (Basic, Weighted)(shares)	–	–	309	211	75	41	–	–	–	–	–	11	2.38	2.38	2.38	–	–
Shares Outstanding (Diluted, Weighted)(shares)	663	625	309	211	75	41	31	18	18	18	15	11	2.38	2.38	2.38	–	–
EBITDA	–	-3.63	-1.45	-4.92	-2.99	-14	-16	-0.95	–	–	–	-3.97	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -88.8%
Operating margin: -170.1%
Net margin: -666.2%
Return on equity, FY2025: 44.6%

Financial strength

Current ratio: 0.04
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.0%

Valuation

P/E ratio: –
Price to sales: 0.80
Price to book: –
Dividend yield: –